Immutep Reported TACTI-004 Futility Analysis Was "On Track" in January 2026 -- Weeks Later the Trial Was Halted After Failing to Meet Efficacy Endpoints

NEW YORK, March 18, 2026 /PRNewswire/ -- Shareholders of Immutep Ltd. (NASDAQ: IMMP) who lost money are urged to act now. On January 30, 2026, Immutep filed a 6-K stating that completion of the futility analysis for its Phase III TACTI-004 trial was "on track for the first quarter of CY2026." On March 13, 2026, the Independent Data Monitoring Committee recommended halting the trial entirely after the interim futility analysis showed the drug was unlikely to meet its efficacy endpoints -- and the stock collapsed approximately 80-90%. Those who suffered a loss on IMMP are encouraged to submit their information here. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

The timeline raises a stark contrast between what investors were told and what followed. In its January 30, 2026 6-K filing, Immutep described "strong operational progress" for the TACTI-004 (KEYNOTE-F91) Phase III trial of eftilagimod alfa in first-line non-small-cell lung cancer. The Company characterized the futility analysis as proceeding on schedule. Just six weeks later, the IDMC disclosed that the analysis had determined the trial was unlikely to meet its primary efficacy endpoints and recommended halting enrollment.

Immutep made no public disclosure between the January 30 filing and the March 13 announcement indicating any change in the trial's outlook. TACTI-004 was the Company's lead oncology asset. The stock lost approximately 80-90% of its value in a single session following the IDMC recommendation.

Shareholders who purchased IMMP and suffered a loss are encouraged to click here to discuss their legal rights. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

WHY LEVI & KORSINSKY -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

View original content to download multimedia:https://www.prnewswire.com/news-releases/immp-investor-alert-immutep-ltd-securities-fraud-lawsuit---investors-with-losses-may-seek-to-lead-the-class-action-after-management-allegedly-misrepresented-trial-progress-levi--korsinsky-302717925.html

SOURCE Levi & Korsinsky